Reprint
Clear Cell Renal Cell Carcinoma 2022–2023
Edited by
March 2024
220 pages
- ISBN978-3-7258-0475-7 (Hardback)
- ISBN978-3-7258-0476-4 (PDF)
This book is a reprint of the Special Issue Clear Cell Renal Cell Carcinoma 2022–2023 that was published in
Biology & Life Sciences
Medicine & Pharmacology
Summary
Clear cell renal cell carcinoma is a common tumor in Western countries and an appropriate test subject for new therapies. This Special Issue highlights the most up-to-date research into clear cell renal cell carcinoma from different medical perspectives, including its diagnosis, prognosis, and treatment.
Format
- Hardback
License and Copyright
© 2022 by the authors; CC BY-NC-ND license
Keywords
TIME (tumor immune microenvironment); synchronous; metachronous; mRCC (metastatic renal cell carcinoma); PD-L1; immunophenotype; imaging; renal cell carcinoma; biomarker; renal mass; radiomics; radiogenomics; circadian rhythm; clock genes; renal cell carcinoma; immunotherapy; HIF; renal cell carcinoma; immune microenvironment; tumor immunology; immune checkpoint inhibitor; immunotherapy; renal cell carcinoma; cystic renal neoplasm; differential diagnosis; renal cell carcinoma; single-cell RNA-seq; cell-of-origin; tumor microenvironment; stromal cells; immune cells; novel therapies; renal cell carcinoma; predictive biomarkers; prognostic biomarkers; therapeutic monitoring; immune checkpoint inhibitors; VEGF inhibitors; metastatic disease; nitric oxide; signalling; ccRCC; cohort study; partial nephrectomy; radical nephrectomy; perioperative outcomes; mortality; renal cell carcinoma; tumor heterogeneity; immune microenvironment; T cell; mRCC; complement; classical pathway; “aggressive complement” tumor; biomarkers; immunotherapy; cancer; cholesterol; LDL; HDL; VLDL; NPC1; ccRCC; TKI; indirect comparison; Shiny method; reconstructed individual patient data; disease-free survival; renal cell carcinoma; adjuvant setting; n/a